JP2013504623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504623A5 JP2013504623A5 JP2012529823A JP2012529823A JP2013504623A5 JP 2013504623 A5 JP2013504623 A5 JP 2013504623A5 JP 2012529823 A JP2012529823 A JP 2012529823A JP 2012529823 A JP2012529823 A JP 2012529823A JP 2013504623 A5 JP2013504623 A5 JP 2013504623A5
- Authority
- JP
- Japan
- Prior art keywords
- yeast
- based immunotherapy
- agent
- subject
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 38
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 38
- 238000009169 immunotherapy Methods 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 6
- 230000024949 interleukin-17 production Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 230000004044 response Effects 0.000 claims 5
- 102000013691 Interleukin-17 Human genes 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229940100601 interleukin-6 Drugs 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 3
- 230000001024 immunotherapeutic effect Effects 0.000 claims 3
- 102000002227 Interferon Type I Human genes 0.000 claims 2
- 108010014726 Interferon Type I Proteins 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000016978 Orphan receptors Human genes 0.000 claims 1
- 108070000031 Orphan receptors Proteins 0.000 claims 1
- 108091008778 RORγ2 Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24235509P | 2009-09-14 | 2009-09-14 | |
| US24235309P | 2009-09-14 | 2009-09-14 | |
| US61/242,353 | 2009-09-14 | ||
| US61/242,355 | 2009-09-14 | ||
| US28856809P | 2009-12-21 | 2009-12-21 | |
| US61/288,568 | 2009-12-21 | ||
| PCT/US2010/048699 WO2011032119A1 (en) | 2009-09-14 | 2010-09-14 | Modulation of yeast-based immunotherapy products and responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504623A JP2013504623A (ja) | 2013-02-07 |
| JP2013504623A5 true JP2013504623A5 (enExample) | 2013-11-07 |
| JP5913103B2 JP5913103B2 (ja) | 2016-04-27 |
Family
ID=43034390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529823A Active JP5913103B2 (ja) | 2009-09-14 | 2010-09-14 | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8911722B2 (enExample) |
| EP (1) | EP2477647B1 (enExample) |
| JP (1) | JP5913103B2 (enExample) |
| AU (1) | AU2010291985B2 (enExample) |
| CA (1) | CA2774326C (enExample) |
| WO (1) | WO2011032119A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687030B (zh) | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| JP6068368B2 (ja) | 2011-03-17 | 2017-01-25 | グローブイミューン，インコーポレイテッド | 酵母−ブラキュリ免疫治療組成物 |
| EP2720716B1 (en) * | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| CN109010809A (zh) | 2011-08-17 | 2018-12-18 | 全球免疫股份有限公司 | 酵母-muc1免疫治疗组合物及其用途 |
| DE102011121069A1 (de) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
| KR102103319B1 (ko) | 2012-06-26 | 2020-04-22 | 바이오디식스, 인크. | 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법 |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| AU2013359469B2 (en) * | 2012-12-10 | 2019-05-16 | Seattle Biomedical Research Institute | Cell-free biofragment compositions and related systems, devices, and methods |
| MX374829B (es) | 2013-03-19 | 2025-03-06 | Globeimmune Inc | Composición a base de levadura para usarse para tratar cordoma. |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| CA2948803A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
| AU2016205215B2 (en) | 2015-01-09 | 2021-03-11 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| ES2893584T3 (es) * | 2015-06-10 | 2022-02-09 | Univ Tokyo | Adyuvante para vacunas, vacuna y procedimiento de inducción de inmunidad |
| TWI748957B (zh) | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
| US20180250369A1 (en) * | 2015-09-11 | 2018-09-06 | Ventria Bioscience, Inc. | Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| WO2021041575A1 (en) * | 2019-08-26 | 2021-03-04 | Quintana Francisco J | Compositions and uses for engineered therapeutic microbes and associated receptors |
| EP4489774A4 (en) * | 2022-03-08 | 2026-04-29 | Immunitybio Inc | YEAST-BASED VACCINE INJECTED INTRATUMORALLY |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| CA2043472A1 (en) | 1990-06-04 | 1991-12-05 | Mitsutaka Miyabayashi | Electrode for secondary battery |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
| WO1995004542A1 (en) | 1993-08-06 | 1995-02-16 | Cytel Corporation | Cloning and characterization of the complete mage-1 gene |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| EP1756138A4 (en) | 2004-03-05 | 2009-07-01 | Archemix Corp | APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES |
| US20050239134A1 (en) | 2004-04-21 | 2005-10-27 | Board Of Regents, The University Of Texas System | Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein |
| KR20070068460A (ko) | 2004-10-18 | 2007-06-29 | 글로브이뮨 | 만성 ｃ형 간염에 대한 효모계 치료 |
| TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| WO2007008780A2 (en) | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| BRPI0616589A2 (pt) | 2005-09-28 | 2011-06-28 | Zymogenetics Inc | polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória |
| CA2963828A1 (en) | 2005-10-26 | 2007-05-03 | Novartis Ag | Novel use of il-1beta compounds |
| US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| EP1960433A2 (en) | 2005-11-28 | 2008-08-27 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| JP2009518314A (ja) | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法 |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| TW200806789A (en) | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
| WO2007130493A2 (en) * | 2006-05-03 | 2007-11-15 | Regents Of The University Of Colorado | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| WO2008019061A2 (en) | 2006-08-03 | 2008-02-14 | Vaccinex, Inc. | Anti-il-6 monoclonal antibodies and uses thereof |
| NZ574804A (en) * | 2006-08-11 | 2012-02-24 | Schering Corp | Antibodies to il-17a |
| CA2662862A1 (en) | 2006-08-25 | 2008-02-28 | Zymogenetics, Inc. | Treatment of aplastic anemia |
| US20100093076A1 (en) | 2006-08-25 | 2010-04-15 | Moore Margaret D | Soluble il-27 receptor |
| AU2007310777A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | IL-21 variants |
| US20100150862A1 (en) | 2006-12-07 | 2010-06-17 | Schering Corporation | Methods of modulating maternal-fetal tolerance |
| CA2672386A1 (en) | 2006-12-13 | 2008-06-19 | Ablynx N.V. | Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex |
| EP2109620B1 (en) | 2006-12-21 | 2012-08-22 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| CN101687030B (zh) | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| CA2679588A1 (en) | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| GB0707505D0 (en) | 2007-04-18 | 2007-05-30 | Medical Res Council | Antibodies against il-25 |
| ES2465223T3 (es) | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
| WO2009047360A1 (en) | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
| WO2009060282A2 (en) | 2007-11-06 | 2009-05-14 | Orchid Research Laboratories Limited | Stilbene derivatives as pstat3/il-6 inhibitors |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009100035A2 (en) | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| EP2096438A1 (en) * | 2008-02-28 | 2009-09-02 | Martin Thurnher | Methods for prognosing the status of patients |
| WO2009132821A1 (en) | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| JP2011520898A (ja) | 2008-05-13 | 2011-07-21 | ノビミューン エスアー | 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法 |
| CN102149403A (zh) | 2008-05-23 | 2011-08-10 | 惠氏有限责任公司 | 利用白介素-21受体结合蛋白的治疗方法 |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| US20130121964A1 (en) | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
-
2010
- 2010-09-14 US US13/395,965 patent/US8911722B2/en active Active
- 2010-09-14 WO PCT/US2010/048699 patent/WO2011032119A1/en not_active Ceased
- 2010-09-14 AU AU2010291985A patent/AU2010291985B2/en active Active
- 2010-09-14 JP JP2012529823A patent/JP5913103B2/ja active Active
- 2010-09-14 EP EP10755290.3A patent/EP2477647B1/en active Active
- 2010-09-14 CA CA2774326A patent/CA2774326C/en active Active
-
2014
- 2014-11-10 US US14/536,903 patent/US10117915B2/en active Active
-
2018
- 2018-09-27 US US16/143,710 patent/US20190022197A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Winheim et al. | Impaired function and delayed regeneration of dendritic cells in COVID-19 | |
| Hussain et al. | Similar but different: virtual memory CD8 T cells as a memory‐like cell population | |
| Dwivedi et al. | Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions | |
| Wesa et al. | Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro | |
| Santopaolo et al. | Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months | |
| Perreau et al. | Lack of Mycobacterium tuberculosis–specific interleukin‐17A–producing CD4+ T cells in active disease | |
| Jost et al. | Changes in cytokine levels and NK cell activation associated with influenza | |
| Brown et al. | Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection | |
| Zilliox et al. | Gene expression changes in peripheral blood mononuclear cells during measles virus infection | |
| Leonardi et al. | Akt-Fas to quell aberrant T cell differentiation and apoptosis in Covid-19 | |
| Tan et al. | Deficiency of canonical wnt/β‐catenin signalling in hepatic dendritic cells triggers autoimmune hepatitis | |
| Fujii et al. | Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity | |
| Tong et al. | Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing | |
| Urban et al. | Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses | |
| Moafi et al. | Comparison of pro‐inflammatory cytokines of non‐healing and healing cutaneous leishmaniasis | |
| Alam et al. | CD25-targeted IL-2 signals promote improved outcomes of influenza infection and boost memory CD4 T cell formation | |
| Kirosingh et al. | Malaria-specific type 1 regulatory T cells are more abundant in first pregnancies and associated with placental malaria | |
| García-Piñeres et al. | Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 virus-like particles | |
| Yang et al. | Lung tissue–resident memory T cells optimize protection by IL-10 regulation of innate immunity | |
| Prakash et al. | Dendritic cells from aged subjects display enhanced inflammatory responses to Chlamydophila pneumoniae | |
| Lineburg et al. | Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity | |
| Fernandes et al. | Paracoccidioides brasiliensis interferes on dendritic cells maturation by inhibiting PGE2 production | |
| Devalraju et al. | Defective expansion and function of memory like natural killer cells in HIV+ individuals with latent tuberculosis infection | |
| Griffin | Are T cells helpful for COVID-19: the relationship between response and risk | |
| Akilimali et al. | Cryptococcosis-associated Immune Reconstitution Inflammatory Syndrome is associated with Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T-cells and Monocyte Activation |